Protocol Ledger

NCT06056297 · Phase III · RECRUITING

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Interventional Phase III clinical trial protocol NCT06056297 sponsored by X4 Pharmaceuticals in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-06 Enrollment: 176 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06056297
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)176 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06056297
Protocol FieldVerified Registry Value
NCT IdentifierNCT06056297
Consolidated Lead SponsorX4 Pharmaceuticals
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment176 participants (ESTIMATED)
Registered Start Date2024-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI